Shanghai, China
AffaMed Therapeutics is a biotechnology startup founded in 2019 with the goal to improve medical care in ophthalmology and CNS disorders in China and globally. The company's slogan reflects its ambitious mission to become a leading entity in the field with innovative therapeutics and solutions. They offer a wide range of pharmaceutical, digital, and surgical products to address critical unmet medical needs.
The startup has recently achieved a significant milestone with a $170.00M Series B investment on 30 March 2021. This impressive investment came from a consortium of renowned investors including Partners Investment, Fountainhead Investment Partners, C-Bridge Capital, Superstring Capital, Orion Capital Group, Inc., and Lake Bleu Capital.
AffaMed Therapeutics boasts of a leadership team with deep industry expertise and an extensive track record in high-quality discovery, clinical development, regulatory affairs, manufacturing, commercial operations, and business development. These capabilities have been honed at leading multinational pharmaceutical companies in China and worldwide, positioning the startup for significant growth and impact in the future.
